Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 31 of 2441 for:    NMDA

NMDA Receptors in Motor Learning in Humans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02082912
Recruitment Status : Completed
First Posted : March 10, 2014
Results First Posted : April 22, 2015
Last Update Posted : November 7, 2018
Sponsor:
Information provided by (Responsible Party):
Andrew Butler, PhD, Emory University

Brief Summary:
The purpose of this study is to focus on enhancing upper limb recovery in patients post-stroke by using robotic-assisted therapy in combination with a drug to improve learning new motor skills.

Condition or disease Intervention/treatment Phase
Stroke Drug: D-cycloserine Other: Placebo Device: HandMentor Pro Phase 2

Detailed Description:

Disability after a stroke is common, leaving 65% of patients unable to use their affected hand in daily activities after 6 months. Frequently, these limitations can cause a decreased quality of life. The current standard for intense physical therapy most commonly consists of neurofacilitation techniques and/or task-specific training. Labor-intensive and costly therapy methods are critical barriers to achieving optimal functional outcomes in stroke survivors with motor impairments. Thus, there is a great need to find new ways to enhance the effectiveness of upper limb rehabilitation in patients following stroke.

A promising approach to improving upper extremity motor function utilizing repetitive task practice (RTP) and behavioral shaping along with constraint of the less affected limb is constraint-induced movement therapy (CIMT). Two fundamental limitations of CIMT are the time necessary to deliver and oversee training and the excessive time in which the less affected limb must be constrained. RTP, in the context of CIMT appears to be effective in improving upper extremity motor function of patients with stroke. Alternative approaches such as robotic assisted therapy have been investigated. Recent evidence suggests that improvements in upper-extremity motor function, functional performance in daily tasks and quality of life are seen during a robotic-assisted physical therapy regimen.

Activation of N-methyl-D-aspartate (NMDA) receptors is important for inducing various forms of synaptic plasticity. Application of D-cycloserine (a antibiotic for treating tuberculosis) can enhance certain models of plasticity, such as long-term potentiation. Pharmacologic strategies that enhance NMDA neurotransmission and working memory represent a promising adjuvant therapy in motor rehabilitation of patients after stroke.

The researchers for this study have brought these observations together to generate a working hypothesis that D-cycloserine will enhance certain features of motor learning, information processing speed, episodic and working memory and that this effect can be coupled with physical therapy to facilitate retraining of patients to use impaired limbs to a greater extent and faster than they otherwise might be able to do. The researchers specifically hypothesize that motor (re)learning and cognition can be improved in people with post-stroke hemiparesis by increasing the excitability and synaptic activity of the motor cortex by combining D-cycloserine and robotic-assisted physical therapy.

The purpose of this study is to understand the important factors in rehabilitation therapy that help improve arm function after stroke. This information may help to ultimately reduce disability and improve quality of life in patients with stroke.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: NMDA Receptors in Motor Learning in Humans
Study Start Date : June 2010
Actual Primary Completion Date : April 2012
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Cycloserine

Arm Intervention/treatment
Experimental: D-cycloserine
Subjects will take D-cycloserine and use the HandMentor Pro for robotic therapy
Drug: D-cycloserine
D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks
Other Name: Seromycin

Device: HandMentor Pro
The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).

Active Comparator: Placebo
Subjects will take a placebo pill and use the HandMentor Pro for robotic therapy
Other: Placebo
Placebo pill PO twice weekly (Monday and Wednesday) for three weeks

Device: HandMentor Pro
The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).




Primary Outcome Measures :
  1. Grip Strength of Affected Hand [ Time Frame: Baseline, Day 30 ]
    Hand-grip strength was assessed using the whole hand and was defined as the average of 3 trials using a calibrated Jamar dynamometer (Jamar Dynamometer, Asimow Engineering Co., Santa Monica, CA), with the elbow flexed to 90º and the forearm in a neutral position. This is the standardized method for measuring hand-grip strength with a Jamar dynamometer recommended by the American Society of Hand Therapists. An increase in values means that grip strength is improving.


Secondary Outcome Measures :
  1. Percentage of Stroke Impact Scale (SIS) Categories Meeting Change Criteria [ Time Frame: Baseline, Day 30 ]
    The percentages of Stroke Impact Scale (SIS) physical domain categories meeting criteria for Minimal Clinically Important Difference (MCID) are presented here. The SIS has 59 items in 8 domains of function where respondents rate their degree of difficulty on a 5-point scale, plus a 9th category for stroke recovery (one item, scored from 0 to 100). Scores for each domain are generated so that total scores for each domain range from 0 - 100, where higher scores indicate less difficulty and more recovery. A change of more than 4.5 to 17.8 for the domains was considered a MCID. A higher percentage of SIS categories meeting the MCID criteria indicates increased improvement in that study arm.

  2. Center for Epidemiologic Studies Depression (CES-D) Scale Score [ Time Frame: Baseline, Day 30 ]
    Depressive symptoms were assessed with the Center for Epidemiologic Studies Depression (CES-D) Scale. The CES-S has 20 items rated on a scale of 0 to 3. Total scores range from 0 to 60 with higher scores indicating more depressive symptoms, and a score of 16 or above indicates depression. Baseline scores are presented in the Outcome Measure Data Table and the impact of the study arm at Day 30 is presented in the statistical analysis section.

  3. Display Enhanced Testing for Concussions and Mild Traumatic Brain Injury (mTBI) (DETECT) System Score [ Time Frame: Baseline, Day 30 ]
    Using a computer, helmet with heads-up-display, headphones with audio inputs, and an input unit with two buttons ("Yes" and "No"), the DETECT system combines an immersive environment with neuropsychological tests to assess mTBI. The DETECT software consists of a series of tests evaluating information processing speed, episodic memory, and working memory. Performance is scored based on response type (correct, incorrect, and missing) and response time. Test results are displayed using an internal algorithm that is based on the probability of impairment. Mean baseline z-scores are presented in the Outcome Measure Data Table and the impact of the study arm at Day 30 is presented in the statistical analysis section. A z-score of 0 represents a healthy individual; scores above 0 are the number of standard deviations above the mean, indicating more errors, taking more time, and thus having a higher probability of mild cognitive impairment.

  4. Number of Blocks Moved During the Box and Block Test (BBT) of Affected Arm [ Time Frame: Baseline, Day 30 ]
    Change in functional motor task performance of the arm affected by the stroke was assessed with the Box and Block Test (BBT). The BBT involves dexterous manipulation of objects and voluntary motor control, which improves with upper limb recovery following stroke. The number of blocks moved within 60 seconds are counted. Baseline scores of the mean number of blocks moved are presented in the Outcome Measure Data Table and the impact of the study arm at Day 30 is presented in the statistical analysis section.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • between the ages of 18 and 95 years
  • of either sex
  • of diverse ethnic background
  • have experienced a single unilateral hemispheric or brainstem stroke 3 or more months prior
  • if have experienced more than one stroke, will be accepted only if all strokes are on the same side of the brain, there is no history of a clinical ischemic or hemorrhagic event affecting the other hemisphere, and there is no CT or MRI evidence of more than one a lacune or minor ischemic demyelination affecting the other hemisphere.
  • active motions of the wrist and hand: 10 of wrist extension from a relaxed flexed position; 10 of extension of any two digits at any joint, and 10 of thumb extension at either joint. All active motions must be repeated 3 times within one minute.
  • passive range of motion: 90 of flexion and abduction and 45 external and internal rotation at the shoulder; 45 elbow supination and pronation; elbow extension limited by no more than 30; wrist extension to at least neutral; and digit extension limited by no more than 30.
  • participants will not be required to exhibit any active shoulder or elbow motion
  • ability to sit independently for at least 2 minutes
  • Mini Mental Status Examination score greater than 24
  • Motor Activity Log score less than 3
  • Prospective participants who qualify but who have profound postural instability will undergo the intervention while walking with contact guarding or, when feasible, using their leg and more involved arm to propel a wheelchair.
  • must have a score below 16 on the Center for Epidemiologic Studies Depression Scale
  • must receive a score greater than 25 on the Folstein Mini Mental State Exam.

Exclusion Criteria:

  • any history of more than minor head trauma, subarachnoid hemorrhage, dementia or any other neurodegenerative disease, multiple sclerosis, HIV infection, drug or alcohol abuse, serious medical illness, schizophrenia, major refractory depression
  • insufficient cardiopulmonary function to participate in low-intensity sustained upper extremity exercise
  • severe visual impairment
  • pregnancy
  • breast feeding
  • participation in intensive physical therapy within the prior 12 months
  • inability to understand the potential risks and benefits of the study, personally provide informed consent, and understand and cooperate with treatment
  • participating in other upper extremity rehabilitation, clinical or experimental, during the course of this trial.
  • a score of less than 24 on the Folstein Mini-Mental State Exam
  • a score of less than10 on the Boston Naming Test
  • a first stroke less than 3 months or more than 48 months prior to the initiation of therapeutic intervention
  • less than 18 years old
  • clinical judgment of excessive frailty or lack of stamina
  • serious uncontrolled medical conditions
  • excessive pain in any joint of the more affected extremity that could limit ability to cooperate with the intervention
  • passive range of motion less than 45 degrees for: abduction, flexion or external rotation at shoulder, or pronation of forearm
  • greater than 30 degrees flexion contracture at any finger joint
  • unable to stand independently for 2 min., transfer independently to and from the toilet or perform sit-to-stand
  • current participation in other pharmacological or physical intervention studies, or have received injections of anti-spasticity drugs into upper extremity musculature within the past 3 months, or wish to have drugs injected in the foreseeable future
  • receiving any anti-spasticity drugs orally at the time of expected participation
  • received phenol injections less than 12 months prior to receiving therapy
  • contemplating a move from proximity to the treatment site in less than 6 months from the randomization date.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02082912


Locations
Layout table for location information
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Investigators
Layout table for investigator information
Principal Investigator: Andrew Bulter, PhD Emory University

Publications of Results:
Layout table for additonal information
Responsible Party: Andrew Butler, PhD, Associate Professor, Emory University
ClinicalTrials.gov Identifier: NCT02082912     History of Changes
Other Study ID Numbers: IRB00035176
UL1TR000454 ( U.S. NIH Grant/Contract )
First Posted: March 10, 2014    Key Record Dates
Results First Posted: April 22, 2015
Last Update Posted: November 7, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Cycloserine
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action